Vorapaxar antiplatelets drug

SCH-530348 - SCH530348 - SCH 530348 - •Zontivity

Acute coronary syndrome

All type of patients: 1 trials - TRACER

No demonstrated result

Cardiovascular prevention

All type of patients: 1 trials - TRA-2P TIMI 50

No demonstrated result

intracranial hemorrhage by 92% (harmful effect)

Major bleeding by 45% (harmful effect)

suggested cardiovascular events by 13% (not demonstrated)

suggested myocardial infarction (fatal and non fatal) by 16% (not demonstrated)

suggested cardiovascular death, MI, stroke by 13% (not demonstrated)

See more clinical conditions

Secondary prevention in patients with CAD: 1 trials - TRA-2P TIMI 50

No demonstrated result

intracranial hemorrhage by 92% (harmful effect)

Major bleeding by 45% (harmful effect)

suggested cardiovascular events by 13% (not demonstrated)

suggested myocardial infarction (fatal and non fatal) by 16% (not demonstrated)

suggested cardiovascular death, MI, stroke by 13% (not demonstrated)

Secondary prevention: 3 trials - TRA-2P TIMI 50 - TRA-2P TIMI 50 (no prior stroke sub group) - TRA-2P TIMI 50 (MI subgroup)

No demonstrated result

intracranial hemorrhage by 92% (harmful effect)

Major bleeding by 39% (harmful effect)

suggested cardiovascular events by 15% (not demonstrated)

suggested myocardial infarction (fatal and non fatal) by 16% (not demonstrated)

suggested cardiovascular death, MI, stroke by 13% (not demonstrated)

Secondary prevention in patients with intermittent claudication: 1 trials - TRA-2P TIMI 50

No demonstrated result

intracranial hemorrhage by 92% (harmful effect)

Major bleeding by 45% (harmful effect)

suggested cardiovascular events by 13% (not demonstrated)

suggested myocardial infarction (fatal and non fatal) by 16% (not demonstrated)

suggested cardiovascular death, MI, stroke by 13% (not demonstrated)

Coronary artery disease

Post myocardial infarction

All type of patient: 1 trials - TRA-2P TIMI 50

No demonstrated result

intracranial hemorrhage by 92% (harmful effect)

Major bleeding by 45% (harmful effect)

suggested cardiovascular events by 13% (not demonstrated)

suggested myocardial infarction (fatal and non fatal) by 16% (not demonstrated)

suggested cardiovascular death, MI, stroke by 13% (not demonstrated)